Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jose Ramirez

Interventional Pain Medicine Las Cruces, NM Nurse Practitioner

NPI 1790002830 CMS profile 8394795

3005 Hillrise Dr, Las Cruces, NM 88011

Open in the dashboard

General payments

$714

11 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jose Ramirez of Las Cruces, NM is reported in the CMS Open Payments database as having received $714 across 11 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 20th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $68 3
2024 General $20 1
2023 General $584 5
2022 General $21 1
2021 General $22 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Ramirez
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Jose Ramirez were reported at $68. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Jose Ramirez Interventional Pain Medicine median Middle half National median
2019 $0 $684 $216–$2,079 $163
2020 $0 $382 $122–$1,109 $114
2021 $22 $552 $167–$1,554 $132
2022 $21 $605 $187–$1,924 $149
2023 $584 $671 $195–$1,915 $160
2024 $20 $684 $206–$1,837 $164
2025 $68 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. SPR Therapeutics, Inc $476 3 payments
  2. Abbott Laboratories $112 2 payments
  3. DePuy Synthes Sales Inc. $36 1 payment
  4. Boston Scientific Corporation $22 1 payment
  5. Hikma Pharmaceuticals USA $21 1 payment
  6. BIOTRONIK NRO, Inc. $18 1 payment
  7. Scilex Pharmaceuticals Inc. $16 1 payment
  8. Vanda Pharmaceuticals Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $693 10 payments
  2. Education $21 1 payment
Products named General payments · program years 2021–2025
  1. SPRINT PNS System $476 3 payments
  2. PROCLAIM $92 1 payment
  3. VA-LCP $36 1 payment
  4. Superion $22 1 payment
  5. Kloxxado $21 1 payment
  6. EPIC $20 1 payment
  7. Prospera $18 1 payment
  8. ZTLido $16 1 payment
  9. FANAPT $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

2,297

Median for Certified Registered Nurse Anesthetist (CRNA): 93

Drug cost

$70,978

Median for Certified Registered Nurse Anesthetist (CRNA): $1,824

Branded share of claims

34.4%

Median for Certified Registered Nurse Anesthetist (CRNA): 7.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ztlido Lidocaine Brand 22 $11,230
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 406 $9,918
Pregabalin Generic 251 $7,244
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 178 $6,522
Lidocaine Generic 56 $5,795
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 24 $5,524
Naloxone Hcl Generic 86 $5,275
Diclofenac Sodium Generic 88 $4,444
Gabapentin Generic 325 $4,126
Oxycodone Hcl Generic 83 $1,578

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 143 Part D prescribers listed as Certified Registered Nurse Anesthetist (CRNA); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$337,045

Medicare's payments for the services billed

Medicare patients

398

Average age 72

Services billed

2,432

236 women, 162 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 31%
Depression 29%
Ischemic heart disease 26%
COPD 23%
Chronic kidney disease 21%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

11 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record